Table 3.

Interaction between plasma folate or vitamin B12 and HPV 16ma and risk of being diagnosed with CIN 2+

Cases vs. non-cases
Plasma folate (ng/mL) or vitamin B12 (pg/mL) and HPV 16m (%) combinationOR (95% CI)bP
Plasma folate (ng/mL) and HPV 16m (%) combination
 Plasma folate <14.29 ng/mL and HPV 16m <11%1.00
 Plasma folate ≥14.29 ng/mL and HPV 16m <11%1.10 (0.54–2.22)0.79
 Plasma folate <14.29 ng/mL and HPV 16m ≥11%0.72 (0.35–1.46)0.36
 Plasma folate ≥14.29 ng/mL and HPV 16m ≥11%0.25 (0.10–0.58)<0.01
Pinteraction0.04
Plasma B12 (pg/mL) and HPV 16m (%) combination
 Plasma vitamin B12 <406.58 pg/mL and HPV 16m <11%1.00
 Plasma vitamin B12 ≥406.58 pg/mL and HPV 16m <11%1.68 (0.80–3.55)0.17
 Plasma vitamin B12 <406.58 pg/mL and HPV 16m ≥11%0.77 (0.37–1.61)0.51
 Plasma vitamin B12 ≥406.58 pg/mL and HPV 16m ≥11%0.40 (0.17–0.88)0.02
Pinteraction0.04
  • aAverage methylation of the promoter and enhancer.

  • bAdjusted for age, race, education, waist circumference, smoking status, use of hormonal contraceptive, lifetime number of sexual partners, and circulating concentrations of vitamin C and total carotene.